Cactus Life Sciences
Fishawack Health Founder's Deep History in Healthcare Communications Blends Nicely with Global Scientific Communications Agency's Upcoming Buy-and-Build Strategy
PRINCETON, NJ / ACCESSWIRE / April 16, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that Oliver Dennis has joined them as Chairman, to work alongside Co-founder, Anurag Goel.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Cactus Life Sciences, headquartered in Princeton, New Jersey was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. "We're delighted to have someone with Oliver's experience of growing businesses join the team," said Anurag. "Cactus Life Sciences is about to undertake an exciting buy and build strategy. And Oliver is the perfect addition with his deep history in healthcare communications having founded Fishawack Health® (now Avalere®)."
During Oliver's tenure at Fishawack, he acquired 17 businesses over 13 years including medical communications and branding agencies, as well as strategic healthcare consultancies and market access and HEOR advisory firms. He led 4 management buy outs to take the business from a start-up to over 1400 people across 22 offices, spanning San Diego to Singapore. Oliver will specifically help shape the future vision for Cactus Life Sciences as the healthcare communications agency partner of the future (strategic, agile, tech-enabled, and outcomes focused) to take on traditional agencies which have lost agility and identity in the pursuit of maximizing profit. He will play an active role in driving the inorganic growth strategy for the business, while pursuing his passion for bringing people together from different businesses and disciplines to collaborate on better outcomes for clients, patients, and our people.
"I've been following Cactus over the last 10 years and they're a great organization. I'm excited to be joining them. They've grown consistently and they have the ambition to become the next generation challenger brand to the traditional players in the market," said Oliver. "This is an opportunity to do something with a greater focus on solving client challenges, improving health outcomes, and nurturing our people."
"Too many companies get to a size where they lose their sense of purpose, values, and forget about individuality. As we work toward transforming Cactus Life Sciences into an agency of the future, we want to ensure that we do so while ensuring that patients and our people are at the core of everything we do," said Elvira D'souza, President of Cactus Life Sciences.
About Cactus Life Sciences (cactuslifesciences.com) Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world─with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes. CACTUS has offices in Princeton, London, Aarhus, Singapore, Beijing, Shanghai, Seoul, Tokyo, and Mumbai.
Contact Information:
Laura Perry
Vice President of Strategy & Marketing
laura.perry@cactusglobal.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India27.10.2025 13:45:00 CET | Press release
Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom